Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECEDENT: Personalized Radiation Directed by Sentinel Node Evaluation in Oral Cavity Squamous Cell Carcinoma
NCT07121595Phase 2Recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jul 2025
- Primary completion
- Jul 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in oral cavity squamous cell carcinoma (OCSCC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Contralateral regional control rate at 1 year. Started Jul 2025; status: recruiting.
02
Conditions
oral cavity squamous cell carcinoma (OCSCC)
Beyond the preview
Go deeper on NCT07121595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07121595.